Weiner H L, Mackin G A, Matsui M, Orav E J, Khoury S J, Dawson D M, Hafler D A
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Science. 1993 Feb 26;259(5099):1321-4. doi: 10.1126/science.7680493.
Multiple sclerosis (MS) is thought to be an autoimmune disease mediated by T lymphocytes that recognize myelin components of the central nervous system. In a 1-year double-blind study, 30 individuals with relapsing-remitting MS received daily capsules of bovine myelin or a control protein to determine the effect of oral tolerization to myelin antigens on the disease. Six of 15 individuals in the myelin-treated group had at least one major exacerbation; 12 or 15 had an attack in the control group. T cells reactive with myelin basic protein were reduced in the myelin-treated group. No toxicity or side effects were noted. Although conclusions about efficacy cannot be drawn from these data, they open an area of investigation for MS and other autoimmune diseases.
多发性硬化症（MS）被认为是一种由识别中枢神经系统髓鞘成分的T淋巴细胞介导的自身免疫性疾病。在一项为期1年的双盲研究中，30名复发缓解型MS患者每日服用牛髓鞘胶囊或对照蛋白，以确定口服髓鞘抗原耐受对该疾病的影响。髓鞘治疗组的15名患者中有6名至少经历了一次严重病情加重；对照组的15名患者中有12名发病。髓鞘治疗组中与髓鞘碱性蛋白反应的T细胞减少。未观察到毒性或副作用。尽管无法从这些数据得出关于疗效的结论，但它们开启了对MS和其他自身免疫性疾病的研究领域。
